TOP2A and non-small cell lung carcinoma: Both Oncomine and GEPIA analysis suggested the aberrant gain of expression of TOP2A in NSCLC, including adenocarcinoma (483 cancer and 347 normal cases analyzed) and squamous cell carcinoma (486 cancer and 338 normal cases analyzed) comparing to normal lung tissues (Fig. 4d).